Main Street Group
IBRX icon

Main Street Group’s ImmunityBio IBRX Stock Holding History

Main Street Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$850 Hold
90
– – ﹤0.01% 794
2026
Q2 		$788 Hold
90
– – ﹤0.01% 767
2026
Q1 		$690 Buy
+90
New +$616 ﹤0.01% 778
2025
Q4 		– Sell
-90
Closed -$221 – 325
2025
Q3 		$221 Buy
90
+39
+76% +$100 ﹤0.01% 768
2025
Q2 		$135 Buy
+51
New +$137 ﹤0.01% 756

Other funds holding IBRX

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Vestor Capital
Vestor Capital Chicago, Illinois $1.59B AUM 24.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
AH
Allen Holding New York $1.15B AUM 24.01% 1-Year Est. Return
Kercheville Advisors
Kercheville Advisors San Antonio, Texas $361M AUM 57.53% 1-Year Est. Return
D.A. Davidson & Co
D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return
Sheets Smith Wealth Management
Sheets Smith Wealth Management Winston-Salem, North Carolina $958M AUM 21.88% 1-Year Est. Return
State of Michigan Retirement System
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Plancorp LLC
Plancorp LLC Saint Louis, Missouri $4.4B AUM 16.7% 1-Year Est. Return

Main Street Group's IBRX Position: Q3 2026 in Review

Main Street Group held its ImmunityBio (IBRX) position steady in Q3 2026 at 90 shares worth $850. The position accounts for ﹤0.01% of the portfolio, ranked #794.

Main Street Group first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 147 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Main Street Group held 90 shares of ImmunityBio worth $850 as of Q3 2026.
  • Main Street Group left its ImmunityBio share count unchanged in Q3 2026.
  • ImmunityBio made up ﹤0.01% of Main Street Group's portfolio in Q3 2026, its #794 holding.
  • Main Street Group first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 147 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Main Street Group's 13F filing for Q3 2026, filed 28 Oct 2026.